Jazz Pharmaceuticals to initiate study of JZP-458 to treat ALL

Jazz Pharmaceuticals is set to initiate a single-arm, pivotal Phase II/III study of JZP-458 as a potential treatment option for acute lymphoblastic leukaemia (ALL) or lymphoblastic lymphoma (LBL) patients.